Actively Recruiting
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Led by Western University · Updated on 2024-06-25
30
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.
CONDITIONS
Official Title
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women with histologically-proven metastatic renal cell carcinoma (any TNM stage with M1)
- Baseline conventional imaging of chest, abdomen, and pelvis with contrast-enhanced CT or MRI within 5 weeks of enrollment (contrast required unless medically contraindicated)
- Unenhanced CT chest acceptable if contrast cannot be used
- Unenhanced MRI abdomen and pelvis acceptable if contrast cannot be used due to renal failure
You will not qualify if you...
- Pregnant or breastfeeding
- Under 18 years of age
- Tumor histology without any clear cell component
- Unable to lie flat for 30 minutes for the scan
- History of prior malignancy except non-melanoma skin cancer
- Unable to provide informed consent
- Inadequate liver function
- Urgent need for systemic or radiation cancer treatment expected to start before PSMA scan
- Previous systemic or radiation cancer therapy except radiation for skin cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada, N6A5W9
Actively Recruiting
Research Team
K
Kaydee Connors
CONTACT
N
Nicole Phillips
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here